Skip to main content
PRME logo

PRME · Prime Medicine, Inc.

Track PRME — free
$3.84 +0.02 (+0.52%) At close · Nov 19
Market Cap
$698.58M
Shares
181.92M
Volume · Nov 19 3.99M Avg daily vol (3M) 4.59M

Price & Indicators

 

Key stats

Close
$3.84
Open
$3.84
Day range
$3.69–4.07
52-week closing range
$2.70–5.36
Average volume, 30 days
5.6M
Short interest
29.1M · 16.0% of shares · 4.8 days
Short volume, last session
48%
Last earnings
Nov 12, 2025
Latest filing
10-Q · Nov 12
Price history
Oct 2022 to Nov 2026

Latest documents

2026
Nov 16
Investor event
First approval targeted next year as clinical catalysts approach

Prime Medicine expects first approval next year for chronic granulomous disease; Wilson disease Phase 1-2 began dosing in October and targets 2027 data, while alpha-1 antitrypsin’s first patient dose is expected end of the year or soon after.

9 source passages
we're going towards our first approval next year. And for an ex vivo program, it's something called chronic granulomous disease. you dosed your first patient in your global phase 1-2 in October. We're guiding to data in 2027. And let's shift gears to alpha-1 antitrypsin. Yeah, so we'll announce first patient dose. And for this program, if you think about the IND, you know, cleared in September You look to about two to three months, give or take, for first patient dose. So I'd say we're kind of on pace. So, you know, you can expect something, you know, end of the year or soon after as to getting that first patient in if we hit our timelines. Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Substantial doubt exists about continuing as a going concern

Prime Medicine, Inc. concluded substantial doubt exists about its ability to continue as a going concern for 12 months, reporting $61.2 million in cash, cash equivalents and short-term investments as of September 30, 2026, and $74.8 million including restricted cash.

Revenue $4.21M ▲ 243.9% Net loss $39.04M Diluted EPS -$0.22
Read from the MD&A section
2 source passages
As of September 30, 2026, we had cash, cash equivalents, and investments of $61.2 million, excluding our restricted cash, or $74.8 million, including restricted cash. As a result, we concluded that substantial doubt exists about our ability to continue as a going concern for 12 months from the date these condensed consolidated financial statements are issued. Open the document at this passage
Nov 12
Current report 8-K
$143.7 million raise extends cash runway through 2027

Prime Medicine raised $143.7 million in gross proceeds, reporting pro-forma cash of approximately $209.5 million and a runway through 2027 after dosing the first patient with PM577a and receiving FDA clearance for PM647.

Financial results
5 source passages
Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the quarter ended September 30, 2026 and provided a business update. Closed underwritten public offering, including the full exercise of the underwriters’ option to purchase additional shares, raising $143.7 million in gross proceeds Pro-forma cash, cash equivalents, investments and restricted cash of approximately $209.5 million; cash runway through 2027 First patient dosed in global Phase 1/2 clinical trial of PM577a in Wilson disease, the first clinical study of an in vivo Prime Editing therapy from Prime Medicine; initial clinical data expected in 2027 Received FDA clearance of Investigational New Drug application for PM647 in Alpha-1 Antitrypsin Deficiency; initial clinical data expected in 2027 Open the document at this passage
Nov 12
Current report 8-K Events of Nov 10
Offering Seeks $134.7 Million in Estimated Net Proceeds

Prime Medicine priced 35,714,286 shares at $3.50 per share and granted underwriters an option for 5,357,142 additional shares. Estimated net proceeds, including full option exercise and after underwriting discounts, commissions and offering expenses, are approximately $134.7 million.

Entered into a material agreement Read from the first part of this long document
3 source passages
On November 10, 2026, Prime Medicine, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC and Goldman Sachs & Co. LLC, as representatives of the several underwriters listed on Schedule 1 thereto (collectively, the “Underwriters”), related to an underwritten public offering (the “Offering”) of 35,714,286 shares (the “Underwritten Shares”) of the Company’s common stock, par value $0.00001 per share (“Common Stock”), at a public offering price of $3.50 per share. In addition, the Company has granted the Underwriters an option, exercisable in whole or in part at any time for a period of 30 days from the date of the Underwriting Agreement, to purchase, at the public offering price, less the underwriting discounts and commissions, up to an additional 5,357,142 shares of Common Stock (the “Option Shares” and together with the Underwritten Shares, the “Shares”). The Company estimates that the net proceeds from the Offering, including from the exercise in full of the Underwriters' option to purchase the Option Shares, after deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company, will be approximately $134.7 million. Open the document at this passage
Nov 10
Current report 8-K
Cash and investments estimated at $61.2 million

Prime Medicine estimated cash, cash equivalents and short-term investments of approximately $61.2 million as of September 30, 2026, excluding approximately $13.7 million of restricted cash; the unaudited figures remained subject to quarter-end closing adjustments.

Financial results, Other events
Source passage
On November 10, 2026, Prime Medicine, Inc. (the “Company”) announced that the preliminary unaudited estimates of its cash, cash equivalents, and short-term investments were approximately $61.2 million as of September 30, 2026, excluding its restricted cash of approximately $13.7 million. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$7.06M
Trailing 12 months
Net income (TTM)
−$176.35M
Trailing 12 months
Revenue growth YoY
+243.9%
Year over year
Operating margin
-4,498.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-22.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$54.89M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+10.8%
Year over year · more shares
Price change (1Y)
+3.2%
Trailing year
Short interest
16.0%
Latest settlement · 4.8 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.72
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +9%
above
Price vs 50-day avg +3%
above
RSI (14) 47
neutral
MACD trend Negative
52-week position 43%
mid-range
Momentum
relative strength
Very Strong
1-month return +3%
trailing
6-month return +13%
trailing
YTD return +11%
this year
Relative strength +19%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $4 › 200d $4 — 50d above 200d
Institutional flow Flat
0% holders QoQ · +25 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
16.02% of shares out · ▼ -11.3% MoM · 4.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
188 holders — mid 3-yr range
Squeeze score 66
elevated · 0–100
Fundamentals
Strong
Revenue growth +55%
Y/Y
EPS growth +18%
Y/Y
Free cash flow $-167.1M
Quant / Vol
risk profile
Very High
Volatility 92%
annualized · 1-yr
Max drawdown −42%
past year
ATR 12.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+9% Bullish
Price vs 50-day avg
+3% Bullish
RSI (14)
47 Neutral
MACD trend
Negative Bearish
52-week position
43% Neutral
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross) No cross
50d $4 › 200d $4 — 50d above 200d
Institutional flow Flat
0% holders QoQ · +25 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
16.02% of shares out · ▼ -11.3% MoM · 4.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
188 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3 Now $4 · 43% Range high $5
vs 200-day avg +9% vs 50-day avg +3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash, cash equivalents, investments and restricted cash $108.8M 6/30/2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PRME
Prime Medicine, Inc.
this stock
$698.58M +10.7% +55.3% — 16.0%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.36B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
188
% held
67.9%
Net QoQ
+16.8M sh
Top holder
ARCH Venture Management,…
Held Float
View
Held by Funds
Fund positions
154
View
Short & Settlement
Short Interest Falling
Shares short
29.1M
Days to cover
4.8d
Change
-3.7M sh
View
Short Volume
Short vol %
48%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
8.5K
Value
$44.5K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
53.0%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$4.6M
Net income (FY)
$-201.1M
EPS diluted
$-1.35
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 16, 2026
This year
22

Prime Medicine expects first approval next year for chronic granulomous disease; Wilson disease Phase 1-2 began dosing in October and targets 2027 data, while alpha-1 antitrypsin’s first patient dose is expected end of the year or soon after.

View
Proposed Sales
Value
$7.8M
Shares
522.6K
Filed
Jun 20, 2023
View
Earnings & Events
Webcasts
Last webcast
Nov 16, 2026
View
Investor Relations
Latest news
Prime Medicine Reports Third Quar…
Published
Nov 12, 2026
View

Performance

5D 20D 120D MTD YTD
PRME -1.3% +3.0% +12.9% -18.6% +10.7%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY +4.2% +9.2% +18.6% -13.4% +5.7%
Key facts CIK 1894562 CUSIP 74168J101 13F (30d) 194 filings 179 filers Visit website Investor relations